Your browser doesn't support javascript.
loading
A single-cell landscape of high-grade serous ovarian cancer.
Izar, Benjamin; Tirosh, Itay; Stover, Elizabeth H; Wakiro, Isaac; Cuoco, Michael S; Alter, Idan; Rodman, Christopher; Leeson, Rachel; Su, Mei-Ju; Shah, Parin; Iwanicki, Marcin; Walker, Sarah R; Kanodia, Abhay; Melms, Johannes C; Mei, Shaolin; Lin, Jia-Ren; Porter, Caroline B M; Slyper, Michal; Waldman, Julia; Jerby-Arnon, Livnat; Ashenberg, Orr; Brinker, Titus J; Mills, Caitlin; Rogava, Meri; Vigneau, Sébastien; Sorger, Peter K; Garraway, Levi A; Konstantinopoulos, Panagiotis A; Liu, Joyce F; Matulonis, Ursula; Johnson, Bruce E; Rozenblatt-Rosen, Orit; Rotem, Asaf; Regev, Aviv.
Afiliação
  • Izar B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tirosh I; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Stover EH; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Wakiro I; Ludwig Center for Cancer Research at Harvard, Boston, MA, USA.
  • Cuoco MS; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Alter I; Columbia University Medical Center, Columbia Center for Translational Immunology, New York, NY, USA.
  • Rodman C; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Leeson R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Su MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Shah P; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Iwanicki M; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Walker SR; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Kanodia A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Melms JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mei S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Lin JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Porter CBM; Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, USA.
  • Slyper M; Molecular, Cellular, and Biomedical Sciences, College of Life Sciences and Agriculture, University of New Hampshire, Durham, NH, USA.
  • Waldman J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jerby-Arnon L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ashenberg O; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Brinker TJ; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Mills C; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Rogava M; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Vigneau S; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Sorger PK; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Garraway LA; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Konstantinopoulos PA; German Cancer Research Center, Heidelberg, Germany.
  • Liu JF; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Matulonis U; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rozenblatt-Rosen O; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rotem A; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Regev A; Genentech, San Francisco, CA, USA.
Nat Med ; 26(8): 1271-1279, 2020 08.
Article em En | MEDLINE | ID: mdl-32572264
ABSTRACT
Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor prognosis1. To comprehensively characterize the HGSOC ascites ecosystem, we used single-cell RNA sequencing to profile ~11,000 cells from 22 ascites specimens from 11 patients with HGSOC. We found significant inter-patient variability in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations. We found that the previously described immunoreactive and mesenchymal subtypes of HGSOC, which have prognostic implications, reflect the abundance of immune infiltrates and fibroblasts rather than distinct subsets of malignant cells2. Malignant cell variability was partly explained by heterogeneous copy number alteration patterns or expression of a stemness program. Malignant cells shared expression of inflammatory programs that were largely recapitulated in single-cell RNA sequencing of ~35,000 cells from additionally collected samples, including three ascites, two primary HGSOC tumors and three patient ascites-derived xenograft models. Inhibition of the JAK/STAT pathway, which was expressed in both malignant cells and cancer-associated fibroblasts, had potent anti-tumor activity in primary short-term cultures and patient-derived xenograft models. Our work contributes to resolving the HSGOC landscape3-5 and provides a resource for the development of novel therapeutic approaches.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ascite / Cistadenoma Seroso / Análise de Célula Única Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ascite / Cistadenoma Seroso / Análise de Célula Única Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article